Edwards Lifesciences Files Shelf Registration Statement for Multiple Securities Offering.

Edwards Lifesciences has filed a shelf registration statement to sell multiple types of securities, including common stock, preferred stock, debt securities, warrants, purchase contracts, and units. The offering will be managed by various underwriters, including Goldman Sachs, J.P. Morgan, and Wells Fargo Securities. The filing is subject to regulatory review and does not guarantee the completion of the offering.

Edwards Lifesciences Corporation has filed a shelf registration statement with the Securities and Exchange Commission (SEC) to sell various types of securities, including common stock, preferred stock, debt securities, warrants, purchase contracts, and units. The filing, which was submitted on July 21, 2025 [1], is part of a shelf registration process that allows the company to offer securities from time to time without the need for a new registration statement for each offering.

The registration statement, filed as Form S-3, is a replacement for an expiring registration statement on Form S-3 (No. 333-266272) that was scheduled to expire on July 22, 2025. The new filing indicates that the company may offer these securities separately or together in one or more offerings, with specific terms to be detailed in prospectus supplements.

The securities will be managed by various underwriters, including Goldman Sachs, J.P. Morgan, and Wells Fargo Securities. The prospectus supplement for any offering will describe the plan of distribution and the names of the underwriters involved, along with any applicable fees, commissions, or discount arrangements.

Edwards Lifesciences' common stock is listed on the New York Stock Exchange (NYSE) under the symbol "EW." The company's business, financial condition, results of operations, and prospects may have changed since the dates on which the information in the prospectus was accurate.

Investors are advised to carefully read the prospectus and any accompanying prospectus supplements, along with the documents incorporated by reference, before making any investment decisions. The SEC has not approved or disapproved of the securities or determined if the prospectus is truthful or complete.

References:
[1] https://www.sec.gov/Archives/edgar/data/1099800/000119312525161897/d98050ds3asr.htm